Preston Klassen - Jun 12, 2023 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
President & Head of R & D
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
Jun 12, 2023
Transactions value $
$0
Form type
4
Date filed
6/12/2023, 04:48 PM
Previous filing
Mar 24, 2023
Next filing
Aug 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +350K $0.00 350K Jun 12, 2023 Common Stock 350K $1.46 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares vest one year following the date of grant and the remainder of the shares vest in 36 equal installments on a monthly basis thereafter, such that the option is fully vested three years following the date of grant, subject to the reporting person's continuous service.